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The 2-5 nm Fe(III) oxo-hydroxide core of ferritin is less ordered and readily bioavailable compared to its pure synthetic analogue,
ferrihydrite. We report the facile synthesis of tartrate-modified, nano-disperse ferrihydrite of small primary particle size, but with enlarged or
strained lattice structure (~2.7 Å for the main Bragg peak versus 2.6 Å for synthetic ferrihydrite). Analysis indicated that co-precipitation
conditions can be achieved for tartrate inclusion into the developing ferrihydrite particles, retarding both growth and crystallization and
favoring stabilization of the cross-linked polymeric structure. In murine models, gastrointestinal uptake was independent of luminal Fe(III)
reduction to Fe(II) and, yet, absorption was equivalent to that of ferrous sulphate, efficiently correcting the induced anemia. This process may
model dietary Fe(III) absorption and potentially provide a side effect-free form of cheap supplemental iron.
From the Clinical Editor: Small size tartrate-modified, nano-disperse ferrihydrite was used for efficient gastrointestinal delivery of soluble Fe(III)
without the risk for free radical generation in murine models. This method may provide a potentially side effect-free form iron supplementation.
Crown Copyright © 2014 Published by Elsevier Inc. All rights reserved.
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Unlike most nutritional deficiencies, IDA is not confined
to underdeveloped and developing countries: in the UK,
for example, IDA affects around 5% of adults, nearly 12%
of pre-school children and, in some areas, up to 25% of
school children.1,5,6
To help combat IDA, oral iron supplementation needs to be
well tolerated, cheap, safe and effective but current prepara-
tions fail in at least one of these criteria. Simple ferrous iron
[Fe(II)] salts are most commonly used as these are inexpensive
and the iron is well absorbed. However, they have lately come
under the spotlight in high-profile intervention trials as they
may enhance systemic infection rates, induce undesirable
changes to commensal bacteria of the colon and increase pro-
inflammatory signaling of the gut epithelium.7-10 Some forms
of ferric iron [Fe(III)] (e.g. ferric pyrophosphate) are
considered safer and better tolerated in the gut lumen than
Fe(II) but are poorly absorbed.11-14 Chelation may overcome
the issue of oral Fe(III) bioavailability but then marked
enhancement of colon cancer risk is seen in rodent models
using chelates of Fe(III) EDTA15 or Fe(III) citrate16 for
example. In pursuit of strategies for optimal oral Fe
supplementation we considered the chemical speciation of dietary
Fe(III) and its processing in the gastrointestinal tract. In this respect,
carefully designed studies have shown that Fe(III) is well absorbed
from ferritin.17-19 Ferritin is the broadly conserved biological
storage form of iron and, thus, is found in both meat- and plant-
based foods of the human diet: it is composed of a protein shell with
a ferrihydrite-like mineral core.20,21 Ferrihydrite is a poly oxo-
hydroxide Fe(III) nanoparticle (about 2- to 5-nm diameter) with a
precise atomic structure that still remains amatter of debate because
its size and crystallographically defective nature make its definitive
characterization challenging.22-27 Notably, in ferritin, the surface of
the ferrihydrite-like core appears destabilized (i.e. amorphous)
compared to synthetic or geological ferrihydrite20 which must be
related to interactions between the ferritin protein shell and the
ferrihydrite surface and may involve a phosphate-rich surface
layer.28 Indeed themorphology of the ferritinmineral core has been
shown to follow the symmetry of the protein shell.20,29 Such
surface destabilization probably ensures that iron in ferritin is
abnormally labile for an oxo-hydroxide in the presence of protons
or ligands: thus it is rapidly turned over in the cell lysosome andwill
solubilize in gastric acid.17,30-32 However, it is a matter of debate as
to whether the protein shell and ferrihydrite-like core of ferritin
control the slow release of Fe(III) ions from the gastric
environment, or, if ferritin as a whole or as a protein-denuded
mineral nanoparticle is rapidly emptied from the stomach and
endocytosed by the intestinal epithelial cell and broken down intra-
lysosomally.18,32,33 Either way ferritin is an effective, bioavailable
form of dietary iron that has, for example, led to considerable
investment by the Global HarvestPlus Initiative in “bio-fortifica-
tion” which involves the selection of staple food crops with
enriched ferritin expression.34-37
Iron supplementation with pure ferritin would be immensely
challenging due to the required scale of purification or the
complexity of in vitro synthesis, and thus overall costs.
However, synthetically, it may not be necessary to exactlymimic the ferritin molecule. When organic molecules are present
during the pH-induced formation of aquated ferrihydrite they can
do more than simply adsorb to the surface of freshly precipitated
ferrihydrite. Ligands, such as low-molecular-weight organic
acids, may abate the degree of iron–oxygen and hydroxyl
octahedra linking, diminishing the primary particle size and
retarding maturation and crystallization of the cross-linked
polymer of freshly precipitated ferrihydrite.38,39 We show here
that simple aqueous conditions can be identified that allow small
hydroxyl–carboxyl organic ligands to be co-precipitated with
freshly forming ferrihydrite such that the ligand markedly
disrupts ferrihydrite stability and, that in this fashion, bioavail-
able ferritin-core functional-mimetics were readily synthesised.
For downstream applications (i.e. affordable supplementation)
we focussed on cheap, generally recognized as safe (GRAS)
dietary ligands to provide the modifications and we concentrated
on nano-dispersion and enhanced rates of acid dissolution as
initial desirable properties in light of current knowledge on
dietary ferritin as an oral iron source.Methods
Synthesis of solid ferrihydrite materials
The ligand-modified ferrihydrite materials were produced by
co-precipitation and ligand substitution of oxo/hydroxy groups
following the protocol described by Powell et al.38 Briefly, an
acidic concentrated stock solution of Fe(III) chloride was added
to a solution containing the ligand, buffer and 0.9% (wt/vol) of
electrolyte (sodium chloride; NaCl) or, in the case of synthetic
ferrihydrite, simply 0.9% NaCl. The initial pH of the mixture was
always below 2.0, and the iron was fully solubilized. The pH was
then slowly increased by drop-wise addition of a concentrated
solution of NaOH with constant agitation until reaching the
desired final pH (ca. 7.4 for ligand-modified ferrihydrite and 7.4-
8.2 for synthetic ferrihydrite). In the case of synthetic ferrihydrite
the entire mixture was then oven dried at 45 °C for a minimum of
24 h. For the ligand-modified ferrihydrite materials, ultrafiltra-
tion (3,000 Da MWCO, Vivaspin®) followed by one H2OUHP
wash was used to remove excess soluble ligand and buffer, i.e.
non-bound or non-adsorbed to the nanoparticles (≥95%
recovery according to the manufacturer's specifications), before
the material was oven dried (again 45 °C) for at least 24 h.
Physicochemical characterization
Iron content and phase distribution
Total iron content was determined by inductively coupled
plasma optical emission spectrometry (ICP-OES JY 2000,
Horiba Jobin Yvon Ltd., Stanmore, UK). ICP-OES standards
and samples were diluted in 5% HNO3 to concentrations in the
range 0-1000 ppm. Fractionation of the Fe into percentages of
precipitated, nanoparticulate, and soluble Fe, for each of the Fe
materials was achieved by centrifugation and ultrafiltration.
Aqueous suspensions were centrifuged (10,000 × g, 5 min) and
the sediment taken to be the precipitated fraction. In order to
isolate the soluble Fe, and to distinguish it from disperse or
colloidal (i.e. nanoparticulate) Fe, the supernatant was ultra-
filtered (3,000 Da MWCO; 10,000 × g, 10 min). The Fe content
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determined by ICP-OES and expressed as percentage ± SD in
relation to total Fe content as follows:
%ð Þ Fe precipitated½  ¼ Total Fe–Fesupernatant
 
=Total Fe
 
 100
%ð Þ Fe nanoparticulate½  ¼ Fesupernatant–Feultrafiltrate
 
=Total Fe
 
 100
%ð Þ Fe soluble½  ¼ Feultrafiltrateð Þ=Total Fe½   100
The iron materials were further characterized in terms of
particle morphology by high-angle annular dark-field aberration-
corrected scanning transmission electron microscopy (HAADF-
STEM), X-ray diffraction, Fourier transform infrared spectroscopy
(FTIR), electron energy-loss spectroscopy (EELS) and acid
dissolution profiles. These methods are detailed in Supplementary
Materials.
Animal studies
Six-week-old male mice, CD1 strain (Charles Rivers, Kent,
UK), were used for the “ferrozine” study. Mice were housed in
a light- and temperature-controlled room with ad libitum access
to standard pellet diet and water. Animal care and the regulation
of scientific procedures met the criteria laid down by the
United Kingdom Animals (Scientific Procedures) Act 1986.
Iron deficiency was induced by feeding 3- to 4-week-old mice a
purified low-iron diet (Harlan Teklad, USA) with less than
1 mg Fe/kg for at least 2 weeks. Iron absorption studies were
performed on iron-deficient mice fasted for ca. 16 h prior to the
oral Fe dose. The Fe materials were prepared as described
above at 20 mM Fe, labeled with 59Fe (ca. 3.1 MBq) at the time
of synthesis (intrinsic labeling), and administered by oral
gavage directly into the stomach as a single 100-μl dosage.
Two oral doses of 10 mM ferrozine40 or water (control) were
given 1 h prior to and during the gavage with the Fe
compounds. Mice were left for 4 h with free access to drinking
water until sacrifice and tissue collection. The stomach, small
intestine and cecum plus colon were removed. The duodenum
was removed and rinsed with 0.15 M NaCl. Intestinal tissue
samples and duodenal washings were counted for 59Fe using a
LKB Wallac gamma counter. The carcass was counted for 59Fe
in a small animal whole body gamma counter (LIVE-1,
Technical Associates, Canoga Park, CA). Standards were also
measured in both counters to correct for the difference in
sensitivity. Mucosal transfer was the amount of 59Fe in the
carcass expressed as a percentage of administered dose: i.e.
the amount of 59Fe radioactivity in the carcass 4 h after
the gavage and is expressed as percentage of the total
amount of radioactivity that is emptied out of the stomach.
The soluble ferric iron control was Fe(III) nitrilotriacetate
complex (i.e. Fe(III) NTA).
The bioavailability study in rats was conducted by MPI
Research (Michigan, USA) and was approved by the Institu-
tional Animal Care and Use Committee (IACUC) (MPI study
protocol number 1925-001) following United States Animal
Welfare Regulations. Hemoglobin was measured by clinicalpathology as part of a complete blood count (CBC) panel.
The increase in hemoglobin at day 14 was used as a measure
of the bioavailability of the ligand-modified ferrihydrite
in comparison with synthetic ferrihydrite and the current
gold standard for iron supplementation (Fe(II) sulphate). Male
Sprague–Dawley [Crl:CD® (SD)] rats (n = 32) were approx-
imately 21 days old at arrival (Charles River Laboratories).
The animals were housed individually in polyboxes with toys
and fed Block Lab Diet® Certified Rodent Diet #5002
(PMI Nutrition International, Inc), ad libitum during the
acclimation period (not less than 7 days). The control diet,
i.e. the iron-deficient (ID) diet (AIN-93G Purified Rodent Diet,
Dyets Inc., PA, USA) was administered to all animals from day
0 to day 24 (for the complete diet composition see
Supplementary Table 2). The incorporation of the iron
materials into the diets (~30 mg Fe/kgdiet) and pelletization
through extrusion were carried out by Dyets Inc. Other than the
varying Fe compound, the diets were equivalent and conformed
to AIN-93G-purified rodent diet.41
Administration of the test diets, ID diet fortified with Fe(II)
sulphate, ID diet fortified with synthetic ferrihydrite, and ID
diet fortified with tartrate-modified ferrihydrite, began on day
25. Three groups of eight male rats each were administered
the test diets. One additional group of eight animals served as
the no-iron control and continued to receive the un-
supplemented ID diet. The test and control diets were
administered for 14 days (i.e. until day 38). Rats consumed
tap water and the control or test diets ad libitum throughout
the study. Body weights were measured and recorded weekly.
Blood samples for clinical chemistry evaluations were
collected on days −1, 25, and 39. After the study termination
(day 39) the rats were anaesthetized by CO2 inhalation and
animals were euthanized by exsanguination.Results
Iron material characterization
With initial screening in vitro we sought common GRAS
(or “biologically safe”) ligands that would enable the formation
of nano-dispersed, rather than aggregated or agglomerated,
ferrihydrite materials upon titration of an acidic Fe(III)/ligand
solution with base.
To ensure repeatability we used two separate buffers in
parallel, namely adipate and tryptophan. Consistently, 40 mM
Fe(III) and sub-equimolar tartrate yielded nano-dispersed Fe
oxo-hydroxide materials: for optimal yield of the nano-
disperse material the Fe(III)/tartrate ratio was 2:1 and pH
buffered to greater than 7.0 (≥90% yield: open triangles,
Figure 1, A and Supplementary Figure S1A). Buffer alone
(adipate or tryptophan) had no effect and Fe(III) oxo-
hydroxide aggregation and precipitation preceded as normal
(closed circles, Figure 1, A and Supplementary Figure S1A).
We aimed to obtain dry materials that would re-disperse once
aquated at the appropriate pH so, we next confirmed that,
when re-introduced into the original volume of aqueous
solution, the material again was nano-dispersed or precipitat-
ed according to pH in line with the original titration profile
Figure 1. Formation of tartrate-modified ferrihydrite in adipate buffer as a function
of pH. (A) Dispersed or colloidal (i.e. nanoparticulate) iron, determined following
centrifugation and ultrafiltration to remove soluble iron (main panel), and
precipitated (i.e. agglomerated) iron, determined following centrifugation (inset).
Closed squares show synthetic ferrihydrite precipitated from an Fe(III) chloride
solution; open triangles show modified ferrihydrite precipitated from an Fe(III)
chloride solution in the presence of sodium tartrate and adipate buffer (Fe/tartrate/
adipate = 1:0.5:0.5); closed circles and open diamonds show ferrihydrite
precipitated from an Fe(III) chloride solution in the presence of adipate alone (Fe/
adipate = 1:0.5 and 1:1 respectively). (B) Percentage of nanoparticulate iron (main
panel) and precipitated iron (inset) for the synthetic (closed squares) and tartrate-
modified (open triangles) ferrihydritematerials (molar ratios as above) re-suspended
in the original volume of aqueous solution. (A andB)All values are expressed as a
percentageof total iron in the initial solution as described inMethods. (C)Simulated
gastric dissolution at pH 1.0 of dried synthetic ferrihydrite (closed squares) and
tartrate-modified ferrihydrite that hadbeen precipitated in the presence of tartrate and
adipate (open triangles), atmolar ratios as above, and then dried.Datawere obtained
following 5-min ultrafiltration (3000 Da MWCO); data are mean ± SD, n = 3.
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To determine whether acid-driven dissolution was enhanced
with tartrate modification we followed iron solubility in HCl
at pH 1, as recently undertaken by Hilty et al.42 as a proxy
for Fe(III) bioavailability following oral dosing. The tartrate-
modified ferrihydrite showed markedly greater solubility than
similarly prepared ferrihydrite precipitated in the absence of
tartrate (Figure 1, C and Supplementary Figure S1C).
To determine whether nano-dispersion alone or modification
of the ferrihydrite primary particles (i.e. modification of
synthetic ferrihydrite) had occurred during co-precipitation
with tartrate, we used powder X-ray diffraction (XRD),
analytical electron microscopy and Fourier transform infrared
spectroscopy (FTIR). Initial identification of synthetic ferrihy-
drite (i.e. the dried control material without ligand modification)
was performed using powder XRD (Figure 2): Two broad peaks
were present, centered at ~35° and 62° 2θ (2.6 Å and 1.5 Å
respectively), and are characteristic of two-line ferrihydrite.43
Spherical aberration-corrected high-angle annular dark-field
(HAADF) scanning transmission electron microscopy (STEM)
imaging (Figure 2) indicated that the average crystallite sizes
ranged from 2 to 4 nm. This size, and the morphology, were
exactly as expected for two-line ferrihydrite.24 Contrast in
HAADF-STEM images is sensitive to atomic number (to the
power of about 1.7) and spherical aberration correction enables
atomic contrast to be obtained.20 Thus the image of synthetic
ferrihydrite (Figure 2, D) emphasizes the lattice positions of the
iron atoms in this nanocrystalline material (since iron is the
heaviest element in ferrihydrite).
Synthesis, as above, in the presence of tartrate (Fe/
tartrate = 2:1), followed by ultrafiltration (3 kDa MWCO),
washing and drying, yielded a powder XRD pattern with
broader, less well-defined Bragg peaks, shifted to 33° and 61°
2θ respectively (2.7 Å and 1.5 Å; Figure 2). Consistent with
the qualitative changes in broadening of the XRD pattern,
corresponding HAADF-STEM images highlighted the notable
nanoparticle dispersion and a marked decrease in overall
crystallite order and size (to ca. 1-1.5 nm) of the tartrate-
modified ferrihydrite (Figure 2, A and B) compared to
synthetic ferrihydrite (Figure 2, D).
The infrared spectrum of synthetic ferrihydrite (black line,
Figure 3) was entirely consistent with that previously
reported,44,45 whereas that of ferrihydrite precipitated in the
presence of tartrate (Fe/tartrate = 2:1), and then ultrafiltered,
washed and dried (red line, Figure 3), showed a mixed profile of
tartrate (green line, Figure 3) plus ferrihydrite (black line,
Figure 3) but with no evidence of buffer (tryptophan) which,
if present, would show strong unique peaks at ~700 and
3350 cm−1 (blue line, Figure 3): moreover, the tartrate-modified
ferrihydrite (red line, Figure 3) generated only broad tartrate
peaks, distinct to those of sodium tartrate (e.g. the sharp doublet
of ~1100 cm−1; green line, Figure 3). The similarity between the
infrared spectra for tartrate and adipate (particularly at
~3000 cm−1) precludes such discriminatory comparisons when
using the adipate buffer for synthesis.
Transmission electron microscopy (TEM) with electron
energy-loss spectroscopy (EELS) was used to probe the local
iron environments of the ferrihydrite materials (Figure 4). The Fe
Figure 2. Structural characterization of the ferrihydrite. (A-D), High-angle annular dark-field, aberration-corrected, scanning transmission electron microscopy
(HAADF-STEM) images of tartrate-modified ferrihydrite in tryptophan (A, B) or adipate buffer (C), and of synthetic (unmodified) ferrihydrite (D). Scale bars
are 50 nm (A and C) or 2 nm (B and D). (E) X-ray diffraction patterns of synthetic ferrihydrite (black) and tartrate-modified ferrihydrite (red). Both patterns
have peaks characteristic of ferrihydrite, with the synthetic ferrihydrite peaks centred at 35° and 62° 2θ (2.6 Å and 1.5 Å, respectively) and the tartrate-modified
ferrihydrite peaks centered at 33° and 61° 2θ (2.7 Å and 1.5 Å, respectively), indicating expansion of the ferrihydrite lattice. Sodium tartrate is shown in green.
Synthetic ferrihydrite was precipitated from an Fe(III) chloride solution and tartrate-modified ferrihydrite from an Fe(III) chloride solution in the presence of
tartrate and tryptophan buffer (Fe/tartrate/tryptophan = 1:0.5:0.375). Excess ligand and buffer were removed from the modified material by ultrafiltration and
washing prior to drying as described in Methods.
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again consistent with that of synthetic ferrihydrite27,46,47 while
the tartrate-modified ferrihydrite Fe spectrum was almost
identical suggesting that the ferrihydrite (or at least the Fe(III))
nature of the material was retained (Figure 4). An apparent very
minor shift of the Fe L3-peak maxima from 709.5 eV (Fe(III))
toward 707.5 eV (Fe(II)) should be viewed with caution as our
previous data have shown that even with carefully controlled
electron exposure, organic moieties will enhance the suscepti-
bility of ferrihydrite to irradiation damage.27,46,47 The same
should be noted for the carbon and oxygen K-edges at around
285 and 530 eV respectively, although the modified material
shows, as expected, a much greater content of the organic-
derived signals (Figure 4).
Taken together the XRD, STEM, FTIR and EELS data
show that the tartrate-modified ferrihydrite is a disrupted or
strained ferrihydrite structure where the tartrate ligand has
been incorporated into the particles during co-precipitation
and we suggest that this leads to a more acid-labile structure.
Certainly, the core ferrihydrite is smaller and less crystalline
and has larger lattice spacings in the tartrate-modified
material (Figures 2 and 4). Additionally, our data are also
consistent with ligand bonding, between the tartrate, with its
moderate affinity for iron (log Keff = 6.49 at pH 3.54,
20 °C),48,49 and the surface of the ferrihydrite nanoparticles,so inhibiting further crystallization and growth39 and
allowing nano-dispersion in aquated systems (Figure 1).
Bioavailability
Therapeutic supplementation with oral Fe(II) salts (e.g.
ferrous sulphate) induces significant gastrointestinal side
effects in ~30% of subjects affecting compliance and thus
effectiveness.50,51 This issue is considered, mostly to relate to
iron redox cycling in the gut lumen leading to the generation
of reactive oxygen species.52 Iron (III) salts are less prone to
the initiation of redox cycling in this environment but are
insoluble at intestinal pH and thus are poorly absorbed.53 Iron
(III) chelates overcome the solubility issue but are expensive
compared to salts and still undergo reduction at the mucosal
surface, probably via duodenal cytochrome B.54 Here we
show that when given by oral gavage to mice, tartrate-
modified ferrihydrite is absorbed as efficiently as the Fe(III)
chelate, ferric nitrilotriacetate (Fe(III)NTA) (Figure 5, A).
However, when the lumen of the gut was first flooded with
ferrozine, an Fe(II) chelator that traps the luminal/mucosal
surface-reduced iron,40 there was no impact on absorption of
the tartrate-modified ferrihydrite, whereas Fe(III)NTA absorp-
tion was almost completely inhibited, confirming Fe(III)NTA
requirement for reduction prior to uptake, and in contrary to
that of the modified ferrihydrite (Figure 5, A).
Figure 3. Fourier transform infrared (FTIR) spectroscopy of the ferrihydrite.
Synthetic (unmodified) ferrihydrite is shown in black, tryptophan in blue,
sodium tartrate in green and the tartrate-modified ferrihydrite is in red.
Unique tartrate but no tryptophan signatures are revealed in the modified
material. Synthetic and tartrate-modified ferrihydrite were prepared as per
Figure 2.
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ferrihydrite, added to a standard diet at 30 mg Fe/kgdiet, was
able to restore hemoglobin levels over 2 weeks, in line with that
of the gold standard ferrous sulphate (Figure 5, B). Synthetic
ferrihydrite, added to the diet, had no impact on hemoglobin
levels added to the same diet, at the same dose (Figure 5, B).
There was no significant difference in the body weights of the
animals on the tartrate-modified ferrihydrite supplemented diet
in comparison with those on the diet supplemented with ferrous
sulphate (Supplementary Table S1).Discussion
Co-precipitation of metal ion hydroxides and organic
moieties to form metal oxo-hydroxides with a degree of
modification is well established. Typically this involves organic
adsorption onto the freshly formed oxo-hydroxide nanoparticles
which, for small anions or ligands, may enhance the formation of
a meta-stable, crystalline phase.55 For large molecules, such as
polymeric sugars, the surface coat acts to prevent secondary
agglomeration and aggregation, a property that has found
beneficial use in the production of both intravenous and oral
therapeutic iron preparations.56-60 Overall, however, in such
studies the primary particle (crystallite) of the metal oxo-
hydroxide appears pure in its internal structure. In contrast, here
we demonstrate that the polymeric, evolving primary particle of
ferrihydrite, can be rendered impure or “doped” with a low-
molecular-weight organic acid under specific conditions of co-
precipitation. For tartrate the spacing between carboxyl and OH
pairs that Fe ions might bind to during complexation in solution
is similar to the distance between Fe atoms in partially ordered
ferrihydrite.39 This might enable the organic acid to become
trapped in, as well as adsorbed on, precipitating ferrihydriteparticles. Certainly, if hydrolysis proceeds too rapidly the
organic acid ligand fails to be incorporated within the evolving
ferrihydrite particles and, instead, is simply adsorbed onto the
primary particles. At the other extreme, excessive concentration
of ligand may inhibit sufficient hydrolysis of iron. However, at
appropriate ratios of Fe/ligand/OH–, ligand-modified ferrihy-
drite can be achieved, the properties of which differ substantially
to the pure synthetic oxo-hydroxides due to marked changes in
crystallinity, surface charge and stability.
Our data are consistent with the recent studies of Eusterhues
et al.61 who demonstrated that organic ligands may indeed
modify, through inclusion, and disruption of iron octahedral
cross-linking, the inter-atomic bond distances (d-spacings)
and particle size of ferrihydrite. More recently, Mikutta62 has
shown, with similar iron/ligand co-precipitation studies, that
hydroxyl-benzoic acids may trigger the formation of small
ferrihydrite nanoparticles with increased structural strain, but
without altered d-spacing, in equilibrium with a fraction of
lower-molecular-weight Fe(III) hydroxybenzoate complexes. In
our system, however, the ligand-induced strain is sufficient to
alter d-spacing (Figure 2). Furthermore, infrared analysis of
ultrafiltered and washed material, obtained following repeated
centrifugation steps, demonstrates co-association of ferrihydrite
and bound tartrate but not buffer, again consistent with inclusion
of tartrate in the ferrihydrite particles (Figure 3). Taken together
our studies indicate that the active material reported herein is a
ligand-modified form of ferrihydrite and not simply a mixture of
small ferrihydrite particles and low-molecular-weight iron
complexes. Indeed, dissolution studies indicate that all of the
iron, and not just a labile fraction, is rendered soluble under
lysosomal conditions (Figure 1, C). Secondly, ferrozine fails,
entirely, to block intestinal uptake of the iron from tartrate-
modified ferrihydrite (Figure 5, A). This again confirms that
there is no labile Fe(III) fraction associated with the tartrate-
modified ferrihydrite. Ferrozine is an Fe(II) chelator that has
been well shown, both in vivo and in vitro, to markedly inhibit
iron absorption from soluble Fe(III) complexes because these
have an absolute requirement for reduction prior to
absorption.40,63-66 Ferrozine traps the reduced iron (i.e. Fe(II))
and prevents iron absorption but no such effect was seen here
with tartrate-modified ferrihydrite. Thirdly, our recent cellular
studies with electron microscopy and inhibition of cellular
endocytosis, demonstrate significant intestinal cell uptake of
whole nanoparticles.67
The aims of this work were not to mimic the ferrihydrite-like
core of ferritin in appearance or molecular detail but, rather, in
terms of its functional properties that allow for iron bioavail-
ability following ingestion by humans: namely, nanoparticle
dispersion and an enhanced rate of acid-induced dissolution
(and, presumably, chelator-induced dissolution). Phosphate, for
example, which is clearly involved in interactions between the
ferritin protein and its ferrihydrite-like core, probably contributes
to core instability28,68 and can certainly alter the structure of
ferrihydrite following co-precipitation and hydrothermal
annealing.69 However, in our work, additional phosphate ions
provided no further effect over tartrate alone in destabilizing
synthetic ferrihydrite and, when used instead of organic acid
ligand, phosphate was ineffective (data not shown). The
Figure 4. Electron microscopy-based characterization of tartrate-modified ferrihydrite (red) against synthetic ferrihydrite (black). (A) Background-stripped
electron energy-loss spectra (EELS) for the combined C K-edges (285 eV), Ca L2,3-edges (346 eV), O K-edges (530 eV) and Fe L2,3-edges (709.5 eV)
normalized to the continuum intensity post the Fe L2,3-edges. (B) individual background-stripped Fe L2,3-edges. The unaltered shape of the Fe L2,3-edges
indicates that the Fe−(O, OH)6 octahedra remain relatively unchanged after tartrate modification: i.e. the material remains Fe(III). (C and D) Bright-field
transmission electron microscopy (TEM) images of synthetic ferrihydrite (C) and tartrate-modified ferrihydrite (D) agglomerates suspended over holes in the
TEM support film (see supplementary methods for details of specimen preparation). Diffraction contrast from individual crystallites produces dark regions in the
images, the size of which confirms the reduced crystallite size of the modified material. Synthetic ferrihydrite was precipitated from an Fe(III) chloride solution
and tartrate-modified ferrihydrite from an Fe(III) chloride solution in the presence of tartrate and adipate buffer (Fe/tartrate/adipate = 1:0.5:0.5).
a Iron fortificants are added to foods whereas iron supplements are taken
as oral tablets or capsules and typically at higher iron doses than for
fortificants. The materials reported herein are suitable as supplements due to
cheap manufacturing costs but lack the organoleptic properties (typically are
too dark in color) for fortificants.
1535J.J. Powell et al / Nanomedicine: Nanotechnology, Biology, and Medicine 10 (2014) 1529–1538additional factor of the protein shell in ferritin, as opposed to the
protein-free structures reported herein, may explain differing
phosphate sensitivities. In fact, the ligand-destabilized synthetic
ferrihydrite of this report may even better mimic dietary Fe(III)
that is dissolved under acidic, gastric conditions but then re-
precipitates under the much less acidic intestinal conditions:
endogenous ligands abound in the gastrointestinal lumen and
soluble mucin (once referred to as gastroferrin)70 maintains
the ferrihydrite nano-disperse.71 It is noteworthy that, system-
ically, the lysosome is used almost exclusively as the safe
environment for macromolecular iron turnover (e.g. cycling and
re-cycling of hemoglobin, Fe transferrin and ferritin) so it is not
inconceivable that nanoparticulate iron is also acquired by the
gut through intestinal endocytosis and then dissolved by
lysosomal acid and ligands.31,72
In the pursuit of novel, safe iron fortificants, Hilty et al.73 also
demonstrated that nano sized Fe(III)-based particles are more
bioavailable than bulk forms and are handled safely by the gut
without contributing to abnormal tissue loading, although these
authors regarded slow-release, gastric acid dissolution as an
explanation for bioavailability of their Fe(III) nanomaterials.
Whether dissolved in the gastric acid environment or the
intestinal enterocyte lysosome, we concur with Hilty et al.73
that labile forms of nanosized Fe(III) would join the common
(dietary) iron pool before basolateral export from the enterocyte,
ensuring normal homeostatic control of these forms of
iron. Moreover, for these nanomaterials the residual unabsorbed
Fe(III) should transit the remaining gastrointestinal tract in arelatively safe, non-redox active form whether it be as the
original nanostructure or re-precipitated following gastric
emptying. Unlike previously reported nano Fe(III) materials,
produced by flame pyrolysis42,73 and with organoleptic
properties suitable for fortificationa, our approach focuses on
cheap, GRAS reagents and facile synthesis to enable inexpensive
but safe and effective supplementationa which, as the World
Health Organisation has noted, is especially required in
developing and underdeveloped countries.1
Overall, the ligand-modified ferrihydrite materials reported
herein are noteworthy for their very small primary particle size
(b5 nm) and enlarged lattice (circa 2.7 Å for the main Bragg
peak) compared to synthetic ferrihydrite (2.6 Å). These findings
therefore suggest that with appropriate buffers and Fe(III)/ligand/
OH– ratios, conditions can be achieved for ligand inclusion into
the developing ferrihydrite particles, retarding both growth and
crystallization, and favoring stabilization of the cross-linked
polymeric structure. Such materials could have beneficial
application in one key global health priority, namely the
prevention and treatment of iron deficiency anemia without
side effect-inducing redox cycling in the gastrointestinal tract.
Figure 5. Comparative iron absorption and bioavailability of ligand-modified
ferrihydrite. (A) Effect of ferrozine on the absorption of soluble ferric iron
(i.e. Fe(III) NTA) and nanoparticulate, tartrate-modified ferrihydrite (i.e. LM-Fh)
inmale CD1mice.Micewere orally gavagedwith 59Fe-labeled compoundswith
(open bars) or without (closed bars) ferrozine treatment as detailed in Methods.
Values are mean ± SD, n = 7 per group. ***P = 0.0009; ****P b 0.0001;
other comparisons are not significantly different. (B) Hemoglobin levels of
anemic Sprague–Dawley male rats following 2-week treatment with diets
fortified with the different iron compounds: No Fe = control diet with no
supplemental iron (3.1 ± 0.6 mg Fe/kgdiet); Fh = synthetic ferrihydrite
(35.7 ± 0.1 mg Fe/kgdiet); LM-Fh = tartrate-modified ferrihydrite (31.4 ±
0.5 mg Fe/kgdiet); FeSO4 = Fe(II) sulphate (35.8 ± 0.1 mg Fe/kgdiet).
Tartrate-modified ferrihydrite was precipitated from an Fe(III) chloride
solution in the presence of tartrate and adipate buffer (Fe/tartrate/adipate =
1:0.5:0.5). Means with a common letter are not statistically different from
one another, and means labeled with **** are statistically different from the
control diet (No Fe), P b 0.0001, n = 8 per group.
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